Global geographical overlap of aflatoxin and hepatitis C: Controlling risk factors for liver cancer worldwide

Food Additives and Contaminants - Part A

Volumn 30, Issue 3, 2013, Pages 534-540

  Palliyaguru, D L ^a   Wu, F ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

aflatoxin; hepatitis B virus; hepatitis C virus; hepatocellular carcinoma; liver cancer prevention

Indexed keywords

COST EFFECTIVENESS; DISEASES; VIRUSES;

BIOLOGICAL MECHANISMS; CHRONIC HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA; LIVER CANCERS; LOW INCOME COUNTRIES; VIRAL INFECTIONS;

AFLATOXINS;

AFLATOXIN; AFLATOXIN B1; PROTEIN P53;

AFRICA; ARTICLE; ASIA; BURUNDI; CAMEROON; CANCER INCIDENCE; CANCER RISK; CARCINOGENICITY; CHINA; CODON; DEMOCRATIC REPUBLIC CONGO; EGYPT; FOOD CONTAMINATION; GAMBIA; GENE MUTATION; HEPATITIS B; HEPATITIS C; HOSPITAL INFECTION; INDIA; INDONESIA; INFECTION RATE; INFECTION RISK; LIVER CANCER; MALAYSIA; MONGOLIA; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; THAILAND; VACCINATION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 84874463486     PISSN: 19440049     EISSN: 14645122     Source Type: Journal    
DOI: 10.1080/19440049.2012.751630     Document Type: Article

References (40)

1. Abdel-Wahab, M, El-Ghawalby, N, Mostafa, M, Sultan, A, El-Sadany, M, Fathy, O, Salah, T and Ezzat, F. 2007. Epidemiology of hepatocellular carcinoma in lower Egypt, Mansoura Gastroenterology Center. Hepatogastroenterology, 54: 157-162.
2. Abdel-Wahab, M, Mostafa, M, Sabry, M, el-Farrash, M and Yousef, T. 2008. Aflatoxins as a risk factor for hepatocellular carcinoma in Egypt, Mansoura Gastroenterology Center study. Hepatogastroenterology, 55: 1754-1759.
3. Armstrong, GL, Wasley, A, Simard, EP, McQuillan, GM, Kuhnert, WL and Alter, MJ. 2006. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med, 144: 705-714.
4. Baatarkhuu, O, Kim, dY, Bat-Ireedui, P and Han, K-H. 2011. Current situation of hepatocellular carcinoma in Mongolia. Oncology, 81(Suppl. 1): 148-151.
5. Barnes, E, Folgori, A, Capone, S, Swadling, L, Aston, S, Kurioka, A, Meyer, J, Huddart, R, Smith, KTownsend, R. 2012. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med, 4: 115ra1
6. Centers for Disease Control and Prevention (CDC). 2011a. Hepatitis C information for health professionals [Internet]; [cited 2011 Aug 10]. Available from:http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm#section1
7. Centers for Disease Control and Prevention (CDC). 2011b. Incidence of acute hepatitis C, by age group-United States, 1992-2009 [Internet]; [cited 2011 Sep 24]. Available from: http://www.cdc.gov/hepatitis/Statistics/2009Surveillance/Slide4.2.htm
8. Centers for Disease Control and Prevention (CDC). 2011c. National prevention strategy [Internet]; [cited 2011 Sep 9]. Available from:http://www.cdc.gov/hepatitis/hcv/Strategy/NatHepCPrevStrategy.htm
9. Chang, MH, You, SL, Chen, CJ, Liu, CJ, Lee, CM, Lin, SM, Chu, HC, Wu, TC, Yang, SS, Kuo, HS and Chen, DS. 2009. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst, 101: 1348-1355.
10. Eisentein, M. 2011. Vaccines: a moving target. Nature, 474: S16-S17.
11. El-Kafrawy, SA, Abdel-Hamid, M, El-Daly, M, Nada, O, Ismail, A, Ezzat, S, Abdel-Latif, S, Abdel-Hamid, A, Shields, PG and Loffredo, C. 2005. P53 mutations in hepatocellular carcinoma patients in Egypt. Int J Hyg Environ Health, 208: 263-270.
12. Franceschi, S and Raza, SA. 2009. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett, 286: 5-8.
13. Frank, C, Mohamed, MK, Strickland, GT, Lavancy, D, Arthur, RR, Magder, LS, El Khoby, T, Abdel-Wahab, Y, Aly Ohn, ES, Anwar, W and Sallam, I. 2000. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet, 355: 887-891.
14. Groopman, JD, Kensler, TW and Wild, CP. 2008. Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. Annu Rev Public Health, 29: 187-203.
15. Hall, AJ and Wild, CP. 2003. Liver cancer in low and middle income countries. Br Med J, 26: 994-995.
16. Immunization Action Coalition (IAC). 2007. Hepatitis A, B, and C: learn the differences [Internet]; [cited 2012 Dec 12]. Available from:http://www.immunize.org/guide/aov12_appa_hepatitis.pdf
17. International Agency for Research in Cancer (IARC). 2008. GLOBOCAN [Internet]; [cited 2011 Aug 8]. Available from:http://www.iarc.fr/
18. Jeannot E, Boorman GA, Kosyk O, Bradford BU, Shymoniak S, Tumurbaatar B, Weinman SA, Melnyk SB, Tryndyak V, Pogribny IP, Rusyn I. 2012. Increased incidence of aflatoxin B1-induced liver tumors in hepatitis virus C transgenic mice. Int J Cancer. 130:1347-1356
19. Jiang, W, Wang, XW, Unger, T, Forgues, M, Kim, JW, Hussain, SP, Bowman, E, Spillare, EA, Lipsky, MMMeck, JM. 2010. Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int J Cancer, 127: 1011-1020.
20. Khlangwiset, P and Wu, F. 2010. Costs and efficacy of public health interventions to reduce aflatoxin-induced human disease. Food Addit Contam A, 27: 998-1014.
21. Kirk, GD, Lesi, OA, Mendy, M, Szymanska, K, Whittle, H, Goedert, JJ, Hainaut, P and Montesano, R. 2005. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene, 24: 5858-5867.
22. Lata, J. 2010. Chronic liver diseases as liver tumor precursors. Dig Dis, 28: 596-599.
23. Lavanchy, D. 2011. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect, 17: 107-115.
24. Liu, Y, Chang, CH, Marsh, GM and Wu, F. 2012. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer, 48: 2125-2136.
25. Liu, Y and Wu, F. 2010. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect, 118: 818-824.
26. McGivern, DR and Lemon, SM. 2011. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene, 30: 1969-1983.
27. McGlynn, KA and London, WT. 2011. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis, 15: 223-243.
28. Montalto, G, Cervello, M, Giannitrapani, L, Dantona, F, Terranova, A and Castagnetta, LA. 2002. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci, 963: 13-20.
29. Ni, YH and Chen, DS. 2010. Hepatitis B vaccination in children: the Taiwan experience. Pathol Bio (Paris), 58: 296-300.
30. Perz, JF, Armstrong, GI, Farrington, LA, Hutin, YJ and Bell, BP. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol, 45: 529-538.
31. Prati, D. 2006. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol, 45: 607-616.
32. Qian, GS, Ross, RK, Yu, MC, Yuan, JM, Gao, YT, Henderson, BE, Wogan, GN and Groopman, JD. 1994. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev, 3: 3-10.
33. Santos, C and Herrine, SK. 2010. Making the best of a bad situation: early chronic nosocomial HCV infection. Dig Dis Sci, 55: 1509-1511.
34. Sugita-Konishi, Y, Sato, T, Saito, S, Nakajima, M, Tabata, S, Tanaka, T, Norizuki, H, Itoh, Y, Kai, SSugiyama, K. 2010. Exposure to aflatoxins in Japan: risk assessment for aflatoxin B1. Food Addit Contam A, 27: 365-372.
35. Thun, M, DeLancey, JO, Center, MM, Jemal, A and Ward, EM. 2010. The global burden of cancer: priorities for prevention. Carcinogenesis, 31: 100-110.
36. Viviani, S, Carrieri, P, Bah, E, Hall, AJ, Kirk, GD, Mendy, M, Montesano, R, Plymoth, A, Sam, OVan der Sande, M. 2008. 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev, 17: 3216-3223.
37. Viviani, S, Jack, A, Bah, E and Montesano, R. 1997. Hepatocellular carcinoma: a preventable cancer. Epidemiol Prev, 21: 129-136.
38. Wang, LY, Hatch, M, Chen, CJ, Levin, B, You, SL, Lu, SN, Wu, MH, Wu, WP, Wang, LWWang, Q. 1996. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer, 67: 620-625.
39. Wild, CP and Gong, YY. 2010. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis, 31: 71-82.
40. Wu, F. 2004. Mycotoxin risk assessment for the purpose of setting international regulatory standards. Environ Sci Tech, 38: 4049-4055.